ERBB2 and breast carcinoma: The development of HER2 targeting treatments for breast cancer is one of the greatest achievements in modern oncology, and permitted to improve median survival for patients with metastatic, HER2+ breast cancer from about 12 months to more than 50 months in a recently published trial [14].